{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:29:02Z","timestamp":1791332942125,"version":"4.3.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is a lack of suitable small animal models to evaluate human Ab-dependent cellular cytotoxicity (ADCC) in vivo, because of the species incompatibility between humans and animals or due to nonspecific allogeneic immune reactions. To overcome these problems, we established a human tumor-bearing mouse model, using NOD\/Shi-scid, IL-2R\u03b3null (NOG) mice as recipients, in which autologous human immune cells are engrafted and mediate ADCC but in which endogenous murine cells are unable to mediate ADCC. In the present study, we used NOG mice bearing primary adult T cell leukemia\/lymphoma (ATLL) cells and a therapeutic chimeric anti-CCR4 mAb, the Fc region of which is defucosylated to enhance ADCC. We report significant antitumor activity in vivo associated with robust ADCC mediated by autologous effector cells from the same patients. The present study is the first to report a mouse model in which a potent antitumor effect of the therapeutic mAb against primary tumor cells is mediated by autologous human immune cells. Human autologous ADCC in mice in vivo was confirmed by the depletion of human immune cells before ATLL PBMC inoculation. In addition, NOG mice bearing primary ATLL cells presented features identical with patients with ATLL. In conclusion, this approach makes it possible to model the human immune system active in Ab-based immunotherapy in vivo, and thus to perform more appropriate preclinical evaluations of novel therapeutic mAb. Furthermore, the potent ADCC mediated by defucosylated anti-CCR4 mAb, observed here in vivo in humanized mice, will be exploited in clinical trials in the near future.<\/jats:p>","DOI":"10.4049\/jimmunol.0900699","type":"journal-article","created":{"date-parts":[[2009,9,12]],"date-time":"2009-09-12T00:46:53Z","timestamp":1252716413000},"page":"4782-4791","source":"Crossref","is-referenced-by-count":63,"title":["Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD\/Shi-<i>scid<\/i>, IL-2R\u03b3null Mice In Vivo"],"prefix":"10.1093","volume":"183","author":[{"given":"Asahi","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura Bun-in Hospital , Kagoshima,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]},{"name":"Department of Clinical Pathology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Takino","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"2025032603061585900_R1","first-page":"7359","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.","volume-title":"Oncogene","year":"2003"},{"key":"2025032603061585900_R2","first-page":"118","article-title":"Improving the efficacy of antibody-based cancer therapies.","volume-title":"Nat. Rev. Cancer","year":"2001"},{"key":"2025032603061585900_R3","first-page":"503","article-title":"Renaissance of cancer therapeutic antibodies.","volume-title":"Drug Discov. Today","year":"2003"},{"key":"2025032603061585900_R4","first-page":"1139","article-title":"CCR4 as a novel molecular target for immunotherapy of cancer.","volume-title":"Cancer Sci.","year":"2006"},{"key":"2025032603061585900_R5","first-page":"918","article-title":"Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.","volume-title":"Haematologica","year":"2002"},{"key":"2025032603061585900_R6","first-page":"443","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.","volume-title":"Nat. Med.","year":"2000"},{"key":"2025032603061585900_R7","first-page":"754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene.","volume-title":"Blood","year":"2002"},{"key":"2025032603061585900_R8","first-page":"2162","article-title":"The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.","volume-title":"Leukemia","year":"2006"},{"key":"2025032603061585900_R9","first-page":"2127","article-title":"Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.","volume-title":"Cancer Res.","year":"2004"},{"key":"2025032603061585900_R10","first-page":"586","article-title":"Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia\/lymphoma using G-CSF.","volume-title":"Br. J. Haematol.","year":"2008"},{"key":"2025032603061585900_R11","first-page":"3175","article-title":"NOD\/SCID\/\u03b3cnull mouse: an excellent recipient mouse model for engraftment of human cells.","volume-title":"Blood","year":"2002"},{"key":"2025032603061585900_R12","first-page":"53","article-title":"NOD\/Shi-scid IL2r\u03b3null (NOG) mice more appropriate for humanized mouse models.","volume-title":"Curr. Top. Microbiol. Immunol.","year":"2008"},{"key":"2025032603061585900_R13","first-page":"1195","article-title":"Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2R\u03b3null mouse model.","volume-title":"Cancer Immunol. Immunother.","year":"2009"},{"key":"2025032603061585900_R14","first-page":"235","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume-title":"N. Engl. J. Med.","year":"2002"},{"key":"2025032603061585900_R15","first-page":"379","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.","volume-title":"Lancet Oncol.","year":"2006"},{"key":"2025032603061585900_R16","first-page":"4124","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes.","volume-title":"J. Clin. Oncol.","year":"2008"},{"key":"2025032603061585900_R17","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma (ATLL): its close association with skin involvement and unfavorable outcome.","volume-title":"Clin. Cancer Res.","year":"2003"},{"key":"2025032603061585900_R18","first-page":"5494","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.","volume-title":"Clin. Cancer Res.","year":"2004"},{"key":"2025032603061585900_R19","first-page":"3466","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.","volume-title":"J. Biol. Chem.","year":"2003"},{"key":"2025032603061585900_R20","first-page":"7529","article-title":"The CC chemokine receptor 4 as a novel-specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma.","volume-title":"Clin. Cancer Res.","year":"2004"},{"key":"2025032603061585900_R21","first-page":"6494","article-title":"Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory Mycosis fungoides and Sezary syndrome.","volume-title":"Clin. Cancer Res.","year":"2007"},{"key":"2025032603061585900_R22","first-page":"5716","article-title":"Specific recruitment of CCR4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.","volume-title":"Cancer Res.","year":"2006"},{"key":"2025032603061585900_R23","first-page":"6047","article-title":"Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy.","volume-title":"Oncogene","year":"2005"},{"key":"2025032603061585900_R24","first-page":"481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases.","volume-title":"Blood","year":"1977"},{"key":"2025032603061585900_R25","first-page":"2052","article-title":"Regulatory T-cell function of adult T-cell leukemia\/lymphoma cells.","volume-title":"Int. J. Cancer","year":"2007"},{"key":"2025032603061585900_R26","first-page":"1021","article-title":"Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease.","volume-title":"Blood","year":"1998"},{"key":"2025032603061585900_R27","first-page":"6248","article-title":"Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of Fc\u03b3RIIIa functional polymorphism.","volume-title":"Clin. Cancer Res.","year":"2004"},{"key":"2025032603061585900_R28","first-page":"753","article-title":"The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.","volume-title":"Exp. Hematol.","year":"2006"},{"key":"2025032603061585900_R29","first-page":"e326","article-title":"Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies.","volume-title":"PLoS ONE","year":"2007"},{"key":"2025032603061585900_R30","first-page":"212","article-title":"Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.","volume-title":"Int. J. Cancer","year":"2009"},{"key":"2025032603061585900_R31","first-page":"716","article-title":"Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.","volume-title":"Blood","year":"2006"},{"key":"2025032603061585900_R32","first-page":"11712","article-title":"Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.","volume-title":"Cancer Res.","year":"2005"},{"key":"2025032603061585900_R33","first-page":"36","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.","volume-title":"Br. J. Haematol.","year":"2008"},{"key":"2025032603061585900_R34","first-page":"847","article-title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells.","volume-title":"J. Exp. Med.","year":"2001"},{"key":"2025032603061585900_R35","first-page":"4488","article-title":"The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors.","volume-title":"J. Immunol.","year":"2006"},{"key":"2025032603061585900_R36","first-page":"4891","article-title":"Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4\u2212 Tregs, regulate effector T cells using FasL.","volume-title":"J. Immunol.","year":"2007"},{"key":"2025032603061585900_R37","first-page":"942","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.","volume-title":"Nat. Med.","year":"2004"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/183\/7\/4782\/62689315\/9642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/183\/7\/4782\/62689315\/9642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T09:12:31Z","timestamp":1743239551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/183\/7\/4782\/8053076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.0900699","relation":{},"ISSN":["1550-6606","0022-1767"],"issn-type":[{"value":"1550-6606","type":"electronic"},{"value":"0022-1767","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,10]]},"published":{"date-parts":[[2009,10,1]]}}}